No connection

Search Results

ACB vs ARCT

ACB
Aurora Cannabis Inc.
BEARISH
Price
$3.43
Market Cap
$194.5M
Sector
Healthcare
AI Confidence
85%
ARCT
Arcturus Therapeutics Holdings Inc.
BEARISH
Price
$6.68
Market Cap
$189.9M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ACB
--
ARCT
--
Forward P/E
ACB
-31.18
ARCT
-1.61
P/B Ratio
ACB
0.49
ARCT
0.89
P/S Ratio
ACB
0.52
ARCT
2.31
EV/EBITDA
ACB
-6.68
ARCT
0.22

Profitability

Gross Margin
ACB
36.03%
ARCT
-36.79%
Operating Margin
ACB
2.32%
ARCT
-435.06%
Profit Margin
ACB
-22.51%
ARCT
-80.19%
ROE
ACB
-15.51%
ARCT
-28.92%
ROA
ACB
-4.36%
ARCT
-15.5%

Growth

Revenue Growth
ACB
6.8%
ARCT
-68.4%
Earnings Growth
ACB
-94.7%
ARCT
--

Financial Health

Debt/Equity
ACB
0.18
ARCT
0.12
Current Ratio
ACB
3.06
ARCT
6.64
Quick Ratio
ACB
1.05
ARCT
6.5

Dividends

Dividend Yield
ACB
--
ARCT
--
Payout Ratio
ACB
0.0%
ARCT
0.0%

AI Verdict

ACB BEARISH

Aurora Cannabis Inc. (ACB) exhibits severe financial distress signals, underscored by a Piotroski F-Score of 1/9—indicating extreme weakness in operational and financial health. The absence of an Altman Z-Score and persistent negative profitability metrics (ROE: -15.51%, ROA: -4.36%) suggest high bankruptcy risk, especially given the company's negative earnings and declining cash flow. Despite a low price-to-book (0.49) and price-to-sales (0.52), the stock trades at a significant discount due to deteriorating fundamentals and a 96.9% 5-year decline. The lack of analyst coverage and neutral insider activity further erode confidence in near-term recovery.

Strengths
Low price-to-book ratio (0.49) suggests potential undervaluation on a balance sheet basis
Strong gross margin (36.03%) indicates efficient production and cost control
High current ratio (3.06) reflects strong short-term liquidity
Risks
Piotroski F-Score of 1/9 indicates severe financial distress and poor operational performance
Negative ROE (-15.51%) and ROA (-4.36%) reflect persistent unprofitability
Earnings growth has collapsed by -94.70% YoY, with a -93.60% Q/Q decline
ARCT BEARISH

ARCT exhibits severe financial distress despite a modest insider sentiment score and analyst buy consensus. The Piotroski F-Score of 0/9 signals extreme financial weakness, with no positive indicators in profitability, cash flow, or leverage management. The Altman Z-Score is unavailable, but the company's negative margins, declining revenue, and negative earnings suggest high distress risk. While the stock trades below its 52-week high, its 5-year decline of 87.2% and persistent losses underscore deep operational challenges. The Graham Number and intrinsic value are unavailable, indicating no reliable fundamental floor, and the current price reflects speculative expectations rather than sustainable value.

Strengths
Analyst consensus is 'buy' with a target price of $23.44, implying significant upside potential
Insider sentiment is moderately positive at 40/100, suggesting some confidence in long-term prospects
Strong liquidity with a current ratio of 6.64 and quick ratio of 6.50, indicating robust short-term financial health
Risks
Piotroski F-Score of 0/9 indicates extreme financial instability and operational failure across all nine criteria
Revenue declined 68.4% YoY, signaling a severe contraction in business activity
Negative profit margins across all measures: -80.19% (net), -435.06% (operating), -36.79% (gross)

Compare Another Pair

ACB vs ARCT: Head-to-Head Comparison

This page compares Aurora Cannabis Inc. (ACB) and Arcturus Therapeutics Holdings Inc. (ARCT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile